Normal view MARC view ISBD view

Venous Thromboembolism in Adolescent Females: Patient Characteristics.

MedStar author(s):

Citation: Journal of Pediatric & Adolescent Gynecology. 2018 Jun 19Journal of Pediatric & Adolescent Gynecology. 31(5):503-508, 2018 Oct.PMID: 29932972Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment: Obstetrics and Gynecology/Pediatric and AdolescentForm of publication: Journal ArticleMedline article type(s): Journal ArticleYear: 2018 Local holdings: Available online through MWHC library: 2002 - presentISSN:

1083-3188

Name of journal: Journal of pediatric and adolescent gynecologyAbstract: CONCLUSION: Pediatric health care providers should be aware that the period prevalence of VTEs in adolescent females is increasing. Those with a history of estrogen exposure rarely develop VTEs from estrogen alone and they typically have multiple co-morbidities.Copyright (c) 2018. Published by Elsevier Inc.DESIGN, SETTING, PARTICIPANTS: We queried the Pediatric Health Information System database for International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification codes to identify females aged twelve to eighteen years old diagnosed with a VTE or PE from April 2006 - March 2016 in the United States. Patient demographics and comorbidities were also analyzed. We divided our study population into two five-year groups and calculated the change in period prevalence of VTE between those groups.MAIN OUTCOME MEASURES: Primary diagnosis of VTE in the extremities, or PE.RESULTS: The period prevalence of VTE increased from 2.3 adolescent females per 10,000 hospitalized children (Group 1) to 3.3 per 10,000 (Group 2), representing a statistically significant increase of 0.010% (p-value = <0.001). Caucasians and Blacks were most commonly affected. The number of girls affected increased steadily from ages twelve to sixteen and the majority (59.6%) had four or more comorbidities. In patients (N=32) with estrogen exposure, greater than 96% had one or more co-morbidity in addition to estrogen exposure.STUDY OBJECTIVE: Our goal was to describe the period prevalence of VTE and characterize adolescent female patients diagnosed with VTE by describing their age, race, and number of comorbidities. Adolescent females with estrogen exposure were of particular interest since estrogen-containing contraception increases the risk of VTE.All authors: Gomez-Lobo V, Gomez-Lobo V, Hennessey CA, Hennessey CA, Patel VK, Patel VK, Tefera EA, Tefera EAFiscal year: FY2019Fiscal year of original publication: FY2018Digital Object Identifier:

https://dx.doi.org/10.1016/j.jpag.2018.06.007

Date added to catalog: 2018-07-06

Holdings ( 1 )
Title notes ( 8 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	29932972	Available		29932972

Available online through MWHC library: 2002 - present

CONCLUSION: Pediatric health care providers should be aware that the period prevalence of VTEs in adolescent females is increasing. Those with a history of estrogen exposure rarely develop VTEs from estrogen alone and they typically have multiple co-morbidities.

DESIGN, SETTING, PARTICIPANTS: We queried the Pediatric Health Information System database for International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification codes to identify females aged twelve to eighteen years old diagnosed with a VTE or PE from April 2006 - March 2016 in the United States. Patient demographics and comorbidities were also analyzed. We divided our study population into two five-year groups and calculated the change in period prevalence of VTE between those groups.

MAIN OUTCOME MEASURES: Primary diagnosis of VTE in the extremities, or PE.

RESULTS: The period prevalence of VTE increased from 2.3 adolescent females per 10,000 hospitalized children (Group 1) to 3.3 per 10,000 (Group 2), representing a statistically significant increase of 0.010% (p-value = <0.001). Caucasians and Blacks were most commonly affected. The number of girls affected increased steadily from ages twelve to sixteen and the majority (59.6%) had four or more comorbidities. In patients (N=32) with estrogen exposure, greater than 96% had one or more co-morbidity in addition to estrogen exposure.

STUDY OBJECTIVE: Our goal was to describe the period prevalence of VTE and characterize adolescent female patients diagnosed with VTE by describing their age, race, and number of comorbidities. Adolescent females with estrogen exposure were of particular interest since estrogen-containing contraception increases the risk of VTE.

English